Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$4.13
-$0.08(-1.82%)
At close: 4:00 PM EDT
$4.13
-$0.08(-1.82%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume958.79K
Average Volume (3M)5.00M
Market Cap
$1.33B
Enterprise Value$1.64K
Total Cash (Recent Filing)$111.13M
Total Debt (Recent Filing)$330.85M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding321,540,650
10 Day Avg. Volume4,646,837
30 Day Avg. Volume4,999,880
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.29Price Target Upside100.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$443.46M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsSustained revenue expansion and high gross margins indicate growing commercial traction and attractive product economics. If maintained, this combination can provide operating leverage as Afrezza, FURO6, royalties, and manufacturing revenues scale.
Partnered Manufacturing And RoyaltiesSole-manufacturer status and contractual minimums create a more predictable revenue base, while royalties add an asset-light stream tied to partner sales. Together, they diversify dependence on direct Afrezza commercialization and support recurring cash generation.
Expanded Afrezza Market OpportunityPediatric approval broadens Afrezza's eligible population and removes a substantial postmarketing obligation, potentially lowering development burden. The regulatory clearance also supports longer-term market positioning in inhaled insulin and pediatric diabetes care.
Bears Say
Stressed Balance SheetNegative equity and elevated debt reduce financial flexibility and leave less protection if operating performance weakens. Although recent financing added liquidity, the capital structure remains dependent on sustained growth, refinancing access, and disciplined cash management.
Recent Return To Cash Burn And LossesThe reversal from positive prior-year cash flow and earnings to TTM losses indicates that profitability is not yet durable. Continued investment in launches and pipeline programs may consume liquidity before new products generate sufficient recurring returns.
Commercial Access And Execution FrictionHigh prior-authorization dependence can slow patient starts, increase administrative costs, and constrain prescription conversion. Lower utilization per prescription further complicates scaling, making reimbursement improvements and execution critical to realizing FURO6 growth.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.33B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on Aug 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.052.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is -0.06.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 321,540,650 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.29 (100.77% Upside)
$8.29 (100.77% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 867.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.87%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$8.29
▲(100.77% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
9.74% Mutual Funds
15.21% Other Institutional Investors
57.30% Public Companies and
Individual Investors